Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447198 · ClinicalTrials.gov registry record
Cannabidiol (CBD) and Pediatric Epilepsy
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 42
- Enrollment target
NCT02447198 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 42 participants.
The verdict
NCT02447198 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Legislation to allow medical marijuana has had a significant impact on the pediatric population of Colorado. There have been many reported different effects and properties of each of the over 60 known cannabinoids found in marijuana. The main exposures in pediatrics have involved the use of Cannabidiol (CBD) high- and Tetrahydrocannibinol (THC) low-content hash oil in children with epilepsy. The reported benefit of this oil is to have the anticonvulsant properties of CBD without the psychoactive components of THC. Human studies on the efficacy of CBD on epilepsy are few and limited. The investigators' specific aims are the following: * Specific Aim 1: Describe the plasma pharmacokinetics of Cannabidiol (CBD), Tetrahydrocannibinol (THC), and their respective metabolites in pediatric patients with epilepsy. * Specific Aim 2: Describe the plasma pharmacokinetics of other antiepileptic drugs (AEDs) taken in conjunction with CBD in order to evaluate drug interactions. * Specific Aim 3: Describe parental perception of efficacy of CBD on control of epilepsy. The investigators will recruit children and their parents who are currently using or plan to use CBD for their seizure disorder. This study will NOT be providing patients with CBD. Consenting subjects will undergo a number of blood and urine collection that will be analyzed to describe the pharmacokinetics and possible drug interactions of CBD in pediatric epilepsy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-11-02 |
| Est. Completion | 2018-09-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02447198
The ClinicalTrials.gov registry entry for NCT02447198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02447198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02447198 about?
NCT02447198 is a clinical study titled "Cannabidiol (CBD) and Pediatric Epilepsy". Legislation to allow medical marijuana has had a significant impact on the pediatric population of Colorado. There have been many reported different effects and properties of each of the over 60 known cannabinoids found in marijuana. The main exposures in pediatrics have involved the use of Cannabid...
What is the current status of trial NCT02447198?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-11-02. Estimated completion is 2018-09-11.
Who is sponsoring clinical trial NCT02447198?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.